COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Print ISSN:-2393-9079

Online ISSN:-2393-9087


Current Issue

Year 2020

Volume: 7 , Issue: 1

Article Access statistics

Viewed: 584

Emailed: 0

PDF Downloaded: 244

Indian Journal of Pharmacy and Pharmacology

Cost analysis study of commonly used oral hypoglycaemic agents available in India- a pharmacoeconomic study

Full Text PDF Share on Facebook Share on Twitter

Author Details : Dharani Devangi R, Rajesh B, Shashirekha CH

Volume : 4, Issue : 1, Year : 2017

Article Page : 22-26

Suggest article by email


Objectives: To assess the difference in cost percentage variation of various brands of oral hypoglycaemic drugs available in single and in combination in Indian market.
Materials and Methods: An observational study was carried out using ‘Current index in medical specialities’, ‘reference Rx’, & ‘Indian drug referral’ (July-Oct 2014), where in the difference in the maximum and minimum price of a particular drug, manufactured by different pharmaceutical companies, in the same strength, number and dosage form was compared and the percentage variation in price was calculated. Data is analysed using descriptive statistical analysis.
Results: The minimum and maximum percentage price variation for different classes of drugs respectively is as follows: In Single drug therapy, among sulfonylurea group of drugs, Glimepiride (2mg) & Glicazide (80mg) shows maximum and minimum price variation of 730.93% & 165.55% respectively. Among Biguanides & Thiazolidinediones groups, Metformin (500 mg) & Pioglitazone (15mg) show maximum price variation of 402.92% & 483.33% respectively. In α-glucosidases inhibitor group of drugs, Voglibose (0.2mg) shows maximum price variation of 451.28 %. Among newer DPP4 (Dipeptide peptidase 4) inhibitors Vildagliptin (50mg) shows maximum cost variation of 100%. In combination therapies Glimipiride & Pioglitazone combination shows the maximum variation up to 307.7%.
Conclusion: The percentage cost variation of different brands of the same drug manufactured in India is very wide and the reason behind marketing a drug should be directed towards maximizing the benefit of therapy and minimizing negative personal and economic consequences.

Cost analysis, Oral hypoglycaemic drugs, Cost evaluation, Price variation

How to cite : Dharani Devangi R, Rajesh B, Shashirekha Ch, Cost analysis study of commonly used oral hypoglycaemic agents available in India- a pharmacoeconomic study. Indian J Pharm Pharmacol 2017;4(1):22-26

Copyright © 2017 by author(s) and Indian J Pharm Pharmacol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (